Baker Bros. Advisors LP Fibrogen Inc Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $5.97 Million - $49.4 Million	-2,399,300 Reduced 90.97%	238,084 $642,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $20.1 Million - $31.8 Million	1,262,173 Added 91.78%	2,637,384 $49.2 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $7.42 Million - $9.92 Million	559,493 Added 68.59%	1,375,211 $22 Million
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $1.86 Million - $3.03 Million	233,968 Added 40.22%	815,718 $8.61 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $19,232 - $26,864	1,600 Added 0.28%	581,750 $6.99 Million
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $5.76 Million - $8.93 Million	580,150 New	580,150 $8.18 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.